Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00760045 | Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time | PHASE2 | COMPLETED | 40 | — | — | Aug 1, 2008 | - | Jan 6, 2010 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AL-43546 0.15% |
| 2 | EXPERIMENTAL | AL-43546 0.25% |
| 3 | ACTIVE_COMPARATOR | AL-43546 0%(Vehicle) |
| 4 | ACTIVE_COMPARATOR | 0.1% sodium hyaluronate ophthalmic solutio |
| Name | Type | Description |
|---|---|---|
| Hydroxypropyl Guar Galactomannan | DRUG | One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods. |
| 0.1% sodium hyaluronate ophthalmic solution | DRUG | One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods. |
Inclusion Criteria: * Subjects with NIBUT of either eye is 8 seconds or less and other eye is 10 seconds or less at screening test and NIBUT of either eye before instillation in Period I is 10 seconds or less. Exclusion Criteria: * Diagnosis of severe Sjogren's syndrome (history of the use of pun...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 2 | PHASE3 | ABBV-444, REFRESH OPTIVE UD, ABBV-319 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE2 | GRF312 5% |
| Bausch + Lomb Corporation | BLCO | 1 | PHASE2 | Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Perfluorohexyloctane, Vehicle |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Alcon AG | ALC | 2 | NA | Undisclosed |
| Harrow, Inc. | HROW | 1 | — | Undisclosed |